| Literature DB >> 25323695 |
Matthias G J Baud1,2, Enrique Lin-Shiao1,2, Teresa Cardote1, Cynthia Tallant2, Annica Pschibul1, Kwok-Ho Chan1, Michael Zengerle1, Jordi R Garcia1, Terence T-L Kwan2, Fleur M Ferguson2, Alessio Ciulli1,2.
Abstract
Small molecules are useful tools for probing the biological function and therapeutic potential of individual proteins, but achieving selectivity is challenging when the target protein shares structural domains with other proteins. The Bromo and Extra-Terminal (BET) proteins have attracted interest because of their roles in transcriptional regulation, epigenetics, and cancer. The BET bromodomains (protein interaction modules that bind acetyl-lysine) have been targeted by potent small-molecule inhibitors, but these inhibitors lack selectivity for individual family members. We developed an ethyl derivative of an existing small-molecule inhibitor, I-BET/JQ1, and showed that it binds leucine/alanine mutant bromodomains with nanomolar affinity and achieves up to 540-fold selectivity relative to wild-type bromodomains. Cell culture studies showed that blockade of the first bromodomain alone is sufficient to displace a specific BET protein, Brd4, from chromatin. Expansion of this approach could help identify the individual roles of single BET proteins in human physiology and disease.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25323695 PMCID： PMC4458378 DOI： 10.1126/science.1249830
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728